Pmu146 Validation and Representativeness of the Spanish Big-Pac Database: Integrated Computerized Medical Records for Research Into Epidemiology, Medicines and Health Resource Use (Real Word Evidence)

Sicras-Mainar, A.; Enriquez, J.L.; Hernandez, Ivan; Sicras-Navarro, Aram; Aymerich, T.; Leon, Marcelo

doi:10.1016/j.jval.2019.09.1764

Cited by 44 publications

(38 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…External representativity of this database is also guaranteed. 28 A descriptive-univariate statistical analysis was made. Qualitative data were described using absolute and relative frequencies and quantitative data using means, standard deviation, medians, and the 25th and 75th percentiles of the distribution [interquartile range (IQR)].…”

Section: Resultsmentioning

confidence: 99%

Health outcomes and costs in patients with osteoarthritis and chronic pain treated with opioids in Spain: the OPIOIDS real-world study

Sicras‐Mainar¹,

Tornero-Tornero

Negrín³

et al. 2020

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

Objective: The objective of this study was to analyze health outcomes, resource utilization, and costs in osteoarthritis patients with chronic nociceptive pain who began treatment with an opioid in real-world practice in Spain. Methods: We designed a non-interventional, retrospective, longitudinal study with 36 months of follow-up using electronic medical records (EMRs) from primary care centers, of patients aged 18+ years who began a new treatment with an opioid drug in usual practice for chronic pain due to osteoarthritis. Health/non-health resource utilization and costs, treatment adherence, pain change, cognitive functioning, and dependence for basic activities of daily living (BADL) were assessed. Results: A total of 38,539 EMRs [mean age (SD); 70.8 (14.3) years, 72.3% female; 53.3% hip/knee, 25.0% spine, and 21.7% other sites] were recruited. A total of 19.1% of patients remained on initial opioid at 36 months, without significant differences by osteoarthritis site ( p = 0.125). Mean total adjusted cost was €17,915, with 27.7% corresponding to healthcare resources and 72.3% to lost productivity. Hospital admissions for osteoarthritis-related surgical interventions accounted for 15.8% of total healthcare cost. A slight mean pain reduction was observed: –1.3 points, –16.9%, p < 0.001, with increases in cognitive deficit (+3.3%, p < 0.001) and moderate to total dependence for BADL (+15.6%, p < 0.001) in a median duration of opioid use of 203 days (IQR: 89–696). Conclusions: In real-world practice in Spain, opioid use in osteoarthritis was high, but with low adherence. There were meaningful increases in resource use and costs for the National Health System. Pain reduction was modest, whereas cognitive impairment and dependence for BADL increased significantly.

show abstract

Section: Resultsmentioning

confidence: 99%

Health outcomes and costs in patients with osteoarthritis and chronic pain treated with opioids in Spain: the OPIOIDS real-world study

Sicras‐Mainar¹,

Tornero-Tornero

Negrín³

et al. 2020

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

show abstract

“…This database has been validated as an information source for studies of epidemiology, therapeutic adaptation and health/non-healthcare resource use and associated costs. It is representative of the Spanish population [ 19 ].…”

Section: Methodsmentioning

confidence: 99%

Costs and healthcare utilisation of patients with heart failure in Spain

Cervantes

Varela

Palacios

et al. 2020

BMC Health Serv Res

View full text Add to dashboard Cite

Background Increasing the knowledge about heart failure (HF) costs and their determinants is important to ascertain how HF management can be optimized, leading to a significant decrease of HF costs. This study evaluated the cumulative costs and healthcare utilisation in HF patients in Spain. Methods Observational, retrospective, population-based study using BIG-PAC database, which included data from specialized and primary care of people ≥18 years, from seven autonomous communities in Spain, who received care for HF between 2015 and 2019. The healthcare and medication costs were summarized on a yearly basis starting from the index date (1st January 2015), and then cumulatively until 2019. Results We identified 17,163 patients with HF (year 2015: mean age 77.3 ± 11.8 years, 53.5% men, 51.7% systolic HF, 43.6% on NYHA functional class II). During the 2015–2019 period, total HF associated costs reached 15,373 Euros per person, being cardiovascular disease hospitalizations the most important determinant (75.8%), particularly HF hospitalizations (51.0%). Total medication cost accounted for 7.0% of the total cost. During this period, there was a progressive decrease of cardiovascular disease hospital costs per year (from 2834 Euros in 2015 to 2146 Euros in 2019, P < 0.001), as well as cardiovascular and diabetic medication costs. Conclusions During the 2015–2019 period, costs of HF patients in Spain were substantial, being HF hospitalizations the most important determinant. Medication costs represented only a small proportion of total costs. Improving HF management, particularly through the use of drugs that reduce HF hospitalization may be helpful to reduce HF burden.

show abstract

“…Antes de su exportación a BIG-PAC, los RME sufren un riguroso proceso de anonimización en los centros/hospitales de origen, respetando la Ley Orgánica 3/2018, de 5 de diciembre, de Protección de Datos Personales y Garantía de los Derechos Digitales. Atrys Health no tiene acceso a las fuentes de datos primarias (Sicras-Mainar et al, 2019).…”

Section: Pacientes Y Métodosunclassified

Uso concomitante de antivirales de acción directa (AAD) y fármacos con acción sobre el sistema nervioso central: Consideraciones en el perfil actual del paciente con hepatitis C

Sicras‐Mainar

Morillo-Verdugo

2020

Adicciones

View full text Add to dashboard Cite

Pmu146 Validation and Representativeness of the Spanish Big-Pac Database: Integrated Computerized Medical Records for Research Into Epidemiology, Medicines and Health Resource Use (Real Word Evidence)

Cited by 44 publications

References 0 publications

Health outcomes and costs in patients with osteoarthritis and chronic pain treated with opioids in Spain: the OPIOIDS real-world study

Health outcomes and costs in patients with osteoarthritis and chronic pain treated with opioids in Spain: the OPIOIDS real-world study

Costs and healthcare utilisation of patients with heart failure in Spain

Uso concomitante de antivirales de acción directa (AAD) y fármacos con acción sobre el sistema nervioso central: Consideraciones en el perfil actual del paciente con hepatitis C

Contact Info

Product

Resources

About